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and	 the	 dominant	 focus	 on	 motivations	 in	 clinical	 re-
search.	We	explore	participation	as	a	relational	mode	of	
‘being	in	time’	in	Alzheimer's	dementia	prevention—	a	
field	 profoundly	 shaped	 by	 changing	 bodies	 through	
time,	 as	 well	 as	 promissory	 trends	 towards	 future-	
oriented	preventative	medicine.	Analysis	of	 interviews	
with	 older	 adults	 in	 a	 clinical	 trial	 platform	 demon-
strates	that	what	research	‘does’	or	might	(not)	‘do’	for	




identify	 incidental	 possibilities	 for	 care	 that	 emerged	





participation	 is	considered	 in	 terms	of	 ‘therapeutic	af-
fordances’,	which	are	likely	to	fluctuate	as	certain	lived	
or	imagined	futures	unfold.	As	such,	we	open	up	a	con-
ceptual	 space	 to	 think	about	why,	how,	and	critically,	
when	participation	happens,	as	it	emerges	in	relation	to	
lived	times	of	ageing	and	everyday	life.























can	 provide	 depth	 and	 specificity	 to	 the	 sociological	 and	 bioethical	 discourse	 around	 clinical	
research	participation.
The problem of participation
The	recruitment	of	clinical	 research	participants	has	both	expanded	and	 intensified	 in	recent	
years,	and	 the	 identification	and	enrolment	of	 the	 ‘right’	participants	has	become	 the	subject	










the	 relational	 and	 contextual	 nature	 of	 participation.	Thus,	 ideas	 of	 research	 participation	 as	
K E Y W O R D S
affordances,	dementia,	motivations,	research	participation,	
temporality













depth	 focus	 on	 the	 temporal contexts of	 clinical	 research	 participation,	 including	 considering	
how	framings	and	opportunities	associated	with	participation	emerge	as	ongoing	and	iterative	
achievements	across	the	life	course.
Temporal contexts of research participation
Although	Ulrike	Felt	has	argued	for	“[bringing]	time	to	the	forefront	of	debates	on	participation”	
(2016,	p.	178),	work	in	this	line	has	often	focussed	broadly	on	public	engagement	with	temporal	























To	extend	 these	discussions,	we	 revisit	 the	question	of	why	people	participate	 in	biomedi-
cal	research	with	the	aim	of	situating	the	temporalities	of	research	in	the	context	of	the	lived	
times	(Adam,	2006)	of	the	lives	and	social	worlds	of	participants.	We	focus	on	how	participants	









The case: European Prevention of Alzheimer's Dementia (EPAD)
Our	paper	 focuses	on	a	domain,	 that	of	Alzheimer's	dementia	 research,	which	 is	constructed	




























on	 the	 renewal	of	 existing	participation,	 contacting	participants	 in	existing	 research	 studies	
for	 further	 participation	 (Vermunt	 et	 al.,	 2018).	The	 project	 then	 aimed	 to	 achieve	 swift	 re-
cruitment	for	clinical	trials	by	inviting	eligible	participants	in	the	cohort	study	to	take	part	in	
a	clinical	trial.
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METHODOLOGY
In	 this	 article,	 we	 draw	 upon	 interviews	 with	 participants	 in	 the	 EPAD	 study	 cohort	 as	 part	





























participant	panel	 in	one	of	 the	key	study	sites	and	feedback	 incorporated.	The	study	received	
NHS	Research	Ethics	approval	(REC	Reference	19/NW/0315).


























































































Possibilities	 for	 participants	 often	 related	 to	 the	 way	 that	 participation	 practices	 in	 the	 ‘now’	
could	 contribute	 to	 a	 sense	 of	 continuity	 into	 the	 future.	 Lindsay,	 who	 was	 active	 in	 one	
of	 the	 EPAD	 participant	 panels,3	 spoke	 about	 people	 she	 had	 met	 during	 the	 research	 and	
how	they	shared	the	benefit	of	hindsight,	current	access	to	information,	and	their	outlook	on	the	
future:


























The	 feared	 future	of	 living	passively	“as	a	cabbage”	reflects	well-	documented	negative	 imagi-
naries	of	dementia	in	the	face	of	current	expectations	to	be	able-	bodied	and	able-	minded	in	order	
to	age	‘successfully’	(Sandberg,	2021;	Sandberg	&	Marshall,	2017).	This	is	compared	to	the	present	














































or	“a	 few	more	goodies,	 that	 I	might	have”	after	 signing	up	 (Gordon).	This	kind	of	emergent	
benefit	 was	 often	 described	 jokily	 as	 “the	 M.O.T.”—	a	 functional	 check-	up	 where	 you	 would	







































In	 this	 part,	 we	 consider	 how	 the	 future-	oriented	 dimensions	 of	 participation	 produce	 evolv-
ing	affordances	of	observational	and	clinical	trial	research.	Specifically,	we	draw	on	the	unique	
























toms	and	 this	was	a	possibility	of	 counteracting	 those	 symptoms,	 then	we	would	






















The	way	 in	which	participants	 imagined	their	 futures,	and	their	expectations	 for	 trial	partici-
pation	depended	on	the	kind	of	possibilities	and	hopes	available	 to	 them,	and	the	needs	 they	





















was	 not	 the	 only	 participant	 to	 express	 concerns	 about	 the	 need	 to	 anticipate	 an	 uncertain	 and	


















tative	 practice.	 Another	 participant	 imagined	 alternative	 non-	pharmaceutical	 treatments	 that	
she	would	more	comfortably	engage	with,	such	as	aromatherapy,	which	again,	built	on	existing	
practices	of	maintaining	(brain)	health.





















points	 in	 research	 participants’	 lives,	 and	 how	 these	 lives	 create	 the	 possibilities	 for	 research	
extends	beyond	ideas	about	singular	motivations	for	participation,	and	indeed	single	research	
studies.	 It	 demonstrates	 that	 people's	 reasons	 for	 (continued)	 participation	 are	 emergent	 and	
contingent	on	the	multiple	timelines	of	ageing	and	research.	Rather	than	understanding	these	




To	 extend	 our	 analysis	 of	 the	 possibilities	 associated	 with	 these	 situations,	 we	 here	 draw	




and	 movements	 is	 attuned	 to	 specific	 situation	 of	 opportunity	 or	 ‘readiness’	 (Ingold,	 2018,	 p.	







ing	 through,	 relations	 to	 the	 intersecting	 timelines	 of	 research,	 innovation	 and	 everyday	 life.	
The	‘object’	in	this	concrescence	is	the	longitudinal	research	study	and	its	evolving	possibilities	
and	limits	for	research	participants.	As	we	have	shown,	these	possibilities	emerge	through	their	





The	 extended	 and	 overlapping	 temporalities	 we	 describe	 contribute	 to	 differing	 limits	 and	
possibilities	for	care	and	agency,	which	we	describe	in	terms	of	affordances	(Dokumaci,	2017;	
Gibson,	2014;	Ingold,	2000).	The	focus	on	ongoing	practices	of	research	participation	comes	with	



















The	 affordances	 of	 participation	 become	 particularly	 interesting	 as	 they	 are	 considered	 in	
terms	of	how	a	future	experimental	drug	trial	fits	into	participants’	experience	of	their	own	and	
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	4	 Test	 results	 were	 not	 routinely	 given	 to	 participants	 unless	 there	 was	 cause	 for	 clinical	 concern,	 and	 the	
possibility	 of	 clinical	 action.	 For	 example,	 if	 the	 cognitive	 scores	 had	 declined	 to	 a	 point	 where	 the	 partic-
ipant	 would	 be	 diagnosed	 with	 Mild	 Cognitive	 Impairment	 (MCI)	 or	 there	 was	 an	 ‘incidental	 finding’	
such	as	a	deficiency	found	in	the	blood	or	an	abnormality	on	the	brain	that	the	participant's	doctor	should	be	
told	about.
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